CMS officially postpones drugmakers’ best price requirements


On Wednesday, the Center for Medicare and Medicaid Services gave drugmakers six months to comply with Trump-era regulations, requiring them to use the discounts they provide to patients to calculate the “best deal” for drugs under the Medicaid Drug Rebate Program. price”.

new Final rule The best price report will be officially postponed from January 1, 2022 to July 1, 2022.

CMS also includes American Samoa, Northern Mariana Islands, Guam, Puerto Rico, and the Virgin Islands. The United States can join the Medicaid drug tax rebate program as early as January 1, 2023 and April 1, 2024.

CMS raised these delays in May Responding to complaints requires more time to implement the best price plan while still investing resources in public health emergencies.

The agency stated in its latest ruling, “The demand for research, production and distribution of COVID-19 drug treatments and vaccines may divert the financial and human resources of some manufacturers for the development and implementation of system changes, and these changes will require Enter multiple best price quotations. ”

After considering public opinions, stakeholder needs, and various regions and manufacturers, CMS decided to extend the reporting deadline to ensure that complex system changes can be made and to guarantee the opportunity and quality of care for Medicaid patients.

The final date for inclusion is April 1, 2024, and the purpose is to give each region time to decide whether to participate in or abandon the Medicaid program, and its ability to meet its resource needs during the pandemic.

CMS stated in its final rule: “We allow the Territory more time to develop the required system and policy changes to avoid unexpected increases in drug costs and access issues.” “The required system must be able to continuously collect, report, and Validate and track medication usage. In addition, they require extensive advance planning and budgeting.”



Source link